Evidence map›Paper›PMID 42134332›Full record

ArticleCell reports. Medicine2026

Recombinant dimeric PICK1 peptide inhibitors for long-term relief of chronic pain by AAV therapeutics.

Gith Noes-Holt, Kathrine L Jensen, Raquel Comaposada-Baró, Sara E Jager, Mette Richner, Carolyn M Goddard, Marco B K Kowenicki, Line Sivertsen, Lucía Jiménez-Fernández, Rita C Andersen and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Gith Noes-HoltMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Kathrine L JensenMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Raquel Comaposada-BaróMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Sara E JagerMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Mette RichnerDandrite, Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.
Carolyn M GoddardMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Marco B K KowenickiZyneyro, 2200 Copenhagen, Denmark.
Line SivertsenMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Lucía Jiménez-FernándezMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Rita C AndersenMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Jamila H LiljaMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Andreas H LarsenMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Sofie P BoesgaardMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Grace A HouserMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Nikolaj R ChristensenMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Antonio MarinoProteomics Research Infrastructure, Center for Core Facilities, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Anke Tappe-TheodorInstitute of Pharmacology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.
Michael WiererProteomics Research Infrastructure, Center for Core Facilities, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Christian B VægterDandrite, Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.
Rohini KunerInstitute of Pharmacology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.
Kenneth L MadsenMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Andreas T SørensenMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark. Electronic address: andreass@sund.ku.dk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic neuropathic pain's impact, persistence, and limited treatments render it relevant for gene therapy. Here, we describe the development and application of self-assembling dimeric peptide inhibitors of the pain-associated scaffolding protein PICK1 (protein interacting with C-kinase 1), delivered by adeno-associated viral (AAV) vectors. In mice, these peptides prevent mechanical allodynia in inflammatory and neuropathic pain models and reverse neuropathic pain for up to 1 year. Targeting somatosensory pathways relieves pain without overt side effects, while selective transduction of dorsal root ganglion (DRG) neurons is sufficient to provide pain relief. Using proteomic and phosphoproteomic analysis of DRG tissue, we identify regulation of protein kinase C alpha (PRKCA) as a candidate that potentially shapes this pain-relieving phenotype. We finally confirm PICK1 expression and peptide target engagement in human donor tissue, supporting the potential of AAV-encoded PICK1 inhibitors as a clinically meaningful strategy for neuropathic pain conditions.

Indexed as

Carrier ProteinsChronic PainDependovirusNuclear ProteinsPeptidesAnimalsCell Cycle ProteinsDisease Models, AnimalGanglia, SpinalGene Therapy AgentsGenetic TherapyGenetic VectorsHumansHyperalgesiaMaleMiceCarrier ProteinsCell Cycle ProteinsNuclear ProteinsPeptidesPICk1 protein, humanPrkcabp protein, mouseRecombinant ProteinsAAV therapeuticsgene therapyneuropathic painneuropathic pain treatmentpain treatmentPICK1protein interacting with C-kinase 1

Identifiers

PMID42134332
PMCPMC13293952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.